Treace Medical Concepts (TMCI) is jumping 7.5% after investment bank BTIG upgraded the shares to Buy from Neutral. Why BTIG Upgraded the Shares Treace provides technology that facilitates ...
PONTE VEDRA, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in ...
BTIG analyst Ryan Zimmerman upgraded Treace Medical (TMCI) to Buy from Neutral with a $16 price target The company has pivoted away from offering solely Lapiplasty, its leading technology ...
Treace Medical Concepts (TMCI) is jumping 7.5% after investment bank BTIG upgraded the shares to Buy from Neutral. Why BTIG Upgraded the Shares Treace provides technology that facilitates Lapiplasty ...
Stifel Nicolaus analyst Rick Wise maintained a Hold rating on Treace Medical Concepts (TMCI – Research Report) yesterday. The company’s shares closed yesterday at $8.36. Discover outperforming ...
Quite a few insiders have dramatically grown their holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI) over the past 12 months. An insider's optimism about the company's prospects is a positive ...
Treace Medical Concepts, Inc. has a 1-year low of $3.92 and a 1-year high of $15.98. The company has a current ratio of 4.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.51.
Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Free Report) have received a consensus rating of “Hold” from the seven research firms that are covering the stock, Marketbeat reports.
(RTTNews) - Treace Medical Concepts, Inc. (TMCI), a leading innovator in medical technologies for bunion and midfoot deformity treatment, announced on Tuesday the successful completion of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results